learn to play the game., page-22

Hi abdm, the following exerpt from Apr 11 update about FMCG (Sep10) is interesting...

"The broad range of products for which the OBJ technology is being evaluated has required the establishment of a number of new and innovative test models and the recruitment of leading specialists and industry experts familiar with these product categories. Various regulatory pre?]requisites in different parts of the world have introduced additional regulatory requirements which the Company is now addressing."

The "different parts of the world" regulatory issues, I think, are not the US, UK or EEC, given the current experience in the snr mgt team. So I reckon it is either China or India. Here's a read about big-pharma investment in China (albeit from a few years ago) which includes both GSK and Bristol-Myers Squibb.

http://seekingalpha.com/article/106790-big-pharma-steps-up-china-investment

bluebush